FDA approves Roche's oral pill giredestrant for advanced breast cancer
The FDA approved giredestrant with everolimus for a specific advanced breast cancer. In a 207-patient trial it cut the risk of progression or death by 62%.

Read the original
The reporting lives at Reuters. Our summary is checked against it, and we link it on every story.
The FDA approved Roche's oral pill giredestrant, given with everolimus, for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after hormone therapy, Reuters reported. In a late-stage trial of 207 patients, the combination cut the risk of progression or death by 62 percent. The median time without progression was 10 months, compared with 5.5 months without the combination.
The approval is for that specific advanced cancer after hormone therapy. The 207 patients are the trial group behind the 62 percent figure. This is an approval of a treatment studied in that trial, not a claim that every case follows the same course.
Health & Tech in MarylandSilver Spring, MarylandMedical researchPublic healthGood news on November 16
More good news
Other stories in the same neighborhood of kindness.
Health & TechThe FDA approved Lembaz, the first drug shown to help infantile-onset Niemann-Pick C patients live longer
The FDA approved Lembaz, a spinal injection every two weeks. Among 36 treated patients, median survival was 8.5 years versus 4.9 in matched controls. It carries a boxed warning for hearing loss.
Verified · U.S. Food and Drug Administration
Health & TechThe FDA approved a pre-surgery bladder cancer combo
The FDA approved durvalumab, sold as Imfinzi, plus enfortumab vedotin before bladder removal, then durvalumab afterward, for muscle-invasive bladder cancer in patients who cannot take cisplatin or who decline it. In the 695-patient VOLGA trial the combo cut the risk of an event by about half. It is not a cure.
Verified · U.S. Food and Drug Administration
Health & TechThe FDA approved the first drug for a rare kidney disease
The FDA approved Gazyva, obinutuzumab, for adults with primary membranous nephropathy at risk of getting worse, to induce remission of protein in the urine. In a 142-person trial, 36 percent reached complete remission at week 104, compared with 6 percent on tacrolimus. It is not a cure.
Verified · U.S. Food and Drug Administration